Arbutus Biopharma Corp 2026年季度报告

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March31, 2026 OR ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period fromto Commission File Number:001-34949 ARBUTUS BIOPHARMA CORPORATION (Exact Name of Registrant as Specified in Its Charter) 98-0597776(I.R.S. EmployerIdentification No.) British Columbia, Canada(State or Other Jurisdiction ofIncorporation or Organization) 701 Veterans Circle, Warminster, PA 18974 (Address of Principal Executive Offices and Zip Code)267-469-0914 (Registrant’s Telephone Number, Including Area Code) Securities registered pursuant to Section 12(b) of the Act: Title of each classTrading Symbol(s)Name of each exchange on which registeredCommon Shares, without par valueABUSThe Nasdaq Stock Market LLC Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities ExchangeAct of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has beensubject to such filing requirements for the past 90 days. Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant toRule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant wasrequired to submit such files). Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reportingcompany, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,”and “emerging growth company” in Rule 12b-2 of the Exchange Act. If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complyingwith any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). As of May11, 2026, the registrant had 197,537,710common shares, without par value, outstanding. ARBUTUS BIOPHARMA CORPORATION PagePART I. FINANCIAL INFORMATION1ITEM 1.FINANCIAL STATEMENTS (UNAUDITED)1ITEM 2.MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OFOPERATIONS18ITEM 3.QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK36ITEM 4.CONTROLS AND PROCEDURES36PART II. OTHER INFORMATION37ITEM 1.LEGAL PROCEEDINGS37ITEM 1A.RISK FACTORS38ITEM 2.UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS39ITEM 3.DEFAULTS UPON SENIOR SECURITIES39ITEM 4.MINE SAFETY DISCLOSURES39ITEM 5.OTHER INFORMATION39ITEM 6.EXHIBITS40 PART I. FINANCIAL INFORMATION ARBUTUS BIOPHARMA CORPORATION Condensed Consolidated Balance Sheets(Unaudited)(In thousands of U.S. Dollars, except share amounts) ARBUTUS BIOPHARMA CORPORATION Condensed Consolidated Statements of Operations and Comprehensive Income (Loss)(Unaudited)(In thousands of U.S. Dollars, except share and per share amounts) ARBUTUS BIOPHARMA CORPORATION Condensed Consolidated Statements of Stockholders’ Equity(Unaudited)(In thousands of U.S. Dollars, except share amounts) See accompanying notes to the condensed consolidated financial statements. ARBUTUS BIOPHARMA CORPORATION Condensed Consolidated Statements of Stockholders’ Equity(Unaudited)(In thousands of U.S. Dollars, except share amounts) ARBUTUS BIOPHARMA CORPORATION Condensed Consolidated Statements of Cash Flows(Unaudited)(In thousands of U.S. Dollars) ARBUTUS BIOPHARMA CORPORATION Notes to Condensed Consolidated Financial Statements(Tabular amounts in thousands of U.S. Dollars, except share and per share amounts) 1.Nature of business and future operations Description of the Business Arbutus Biopharma Corporation (“Arbutus” or the “Company”) is a clinical-stage biopharmaceutical company focused on infectiousdisease.The Company is currently developing imdusiran(AB-729),its proprietary,GalNAc-conjugated,subcutaneously-deliveredribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B(cHBV). The Company continues to protect and defend its intellectual property, which is the subject of its ongoing lawsuit against Pfizer Inc. andBioNTech SE (collectively, Pfizer/BioNTech) for their use of the Company’s patented lipid nanoparticle (LNP) technology in their COVID-19 messenger ribonucleic acid interference (mRNA)-LNP vaccines. The court issued a claim construction ruling in September 2025, whichconstrued the disputed claim terms in a manner the Company generally considers to be favorable. The parties ar